文献

J-GLOBAL ID：201302236554461202   整理番号：13A0571279

中等度から重度のクローン病に対するヒト抗IL-17Aモノクローナル抗体セクキヌマブ: 無作為化二重盲検プラセボ対照試験の予期しない結果

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial

著者 (40件)： HUEBER Wolfgang (Novartis Inst. for BioMedical Res., Basel, CHE) ,  HUEBER Wolfgang (Secukinumab in Crohn’s Disease Study Group) ,  SANDS Bruce E (Mount Sinai Medical Centre, New York, USA) ,  SANDS Bruce E (Secukinumab in Crohn’s Disease Study Group) ,  LEWITZKY Steve (Novartis Inst. for BioMedical Res., Massachusetts) ,  LEWITZKY Steve (Secukinumab in Crohn’s Disease Study Group) ,  VANDEMEULEBROECKE Marc (Novartis Pharma, Basel, CHE) ,  VANDEMEULEBROECKE Marc (Secukinumab in Crohn’s Disease Study Group) ,  REINISCH Walter (Medical Univ. Vienna, Vienna, AUT) ,  REINISCH Walter (Secukinumab in Crohn’s Disease Study Group) ,  HIGGINS Peter D R (Univ. of Michigan, Michigan, USA) ,  HIGGINS Peter D R (Secukinumab in Crohn’s Disease Study Group) ,  WEHKAMP Jan (IKB Robert-Bosch-Krankenhaus, Stuttgart, DEU) ,  WEHKAMP Jan (Secukinumab in Crohn’s Disease Study Group) ,  FEAGAN Brian G (Univ. of Western Ontario, Ontario, CAN) ,  FEAGAN Brian G (Secukinumab in Crohn’s Disease Study Group) ,  YAO Michael D (National Inst. of Health, Maryland, USA) ,  YAO Michael D (Secukinumab in Crohn’s Disease Study Group) ,  KARCZEWSKI Marek (Solumed Res. Unit, Poznan, POL) ,  KARCZEWSKI Marek (Secukinumab in Crohn’s Disease Study Group) ,  KARCZEWSKI Jacek (Solumed Res. Unit, Poznan, POL) ,  KARCZEWSKI Jacek (Secukinumab in Crohn’s Disease Study Group) ,  PEZOUS Nicole (Novartis Pharma, Basel, CHE) ,  PEZOUS Nicole (Secukinumab in Crohn’s Disease Study Group) ,  BEK Stephan (Novartis Inst. for BioMedical Res., Basel, CHE) ,  BEK Stephan (Secukinumab in Crohn’s Disease Study Group) ,  BRUIN Gerard (Novartis Inst. for BioMedical Res., Basel, CHE) ,  BRUIN Gerard (Secukinumab in Crohn’s Disease Study Group) ,  MELLGARD Bjoern (Novartis Inst. for BioMedical Res., Basel, CHE) ,  MELLGARD Bjoern (Secukinumab in Crohn’s Disease Study Group) ,  BERGER Claudia (Novartis Inst. for BioMedical Res., Basel, CHE) ,  BERGER Claudia (Secukinumab in Crohn’s Disease Study Group) ,  LONDEI Marco (Novartis Genomics Inst. of the Novartis Res. Foundation, San Diego, USA) ,  LONDEI Marco (Secukinumab in Crohn’s Disease Study Group) ,  BERTOLINO Arthur P (Novartis Inst. for BioMedical Res., Basel, CHE) ,  BERTOLINO Arthur P (Secukinumab in Crohn’s Disease Study Group) ,  TOUGAS Gervais (Novartis Pharma, Basel, CHE) ,  TOUGAS Gervais (Secukinumab in Crohn’s Disease Study Group) ,  TRAVIS Simon P L (Univ. of Oxford, Oxford, GBR) ,  TRAVIS Simon P L (Secukinumab in Crohn’s Disease Study Group)
資料名： Gut  (Gut)
巻： 61  号： 12  ページ： 1693-1700  発行年： 2012年12月 
JST資料番号： A0106B  ISSN： 0017-5749  CODEN： GUTTA  資料種別： 逐次刊行物 (A)
発行国： イギリス (GBR)  言語： 英語 (EN)

タイトルに関連する用語 (7件)： クローン病 ,  ヒト ,  モノクローナル抗体 ,  セクキヌマブ ,  二重盲検 ,  プラセボ ,  予期